Market Research Logo

Global H1N1 Vaccines Market 2016-2020

About the H1N1 Vaccines Market

The high level of maturity in the H1N1 vaccines market has renewed the push to develop quadrivalent vaccines that address areas of the market with unmet medical needs. Vaccines that prevent H1N1 have been a long-standing void in the treatment algorithm. Therefore, the introduction advanced vaccines in the next decade will likely alter the global H1N1 vaccines market landscape. Sanofi, AstraZeneca, and VaxInnate have also invested in quadrivalent vaccines, such as Sanofi's VaxiGrip, VaxInnate's VAX2012Q, and AstraZeneca's MEDI-550 vaccine, which will impact the US and Europe markets during the forecast period. Other areas of opportunity for novel entrants include vaccines with improved immune response and immunogenic infant vaccines.

Technavio’s analysts forecast the global H1N1 vaccines market to grow at a CAGR of 4.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global H1N1 vaccines market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent H1N1 infection. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global H1N1 Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Sanofi
  • GSK
  • Astra Zeneca
  • CSL
Other prominent vendors
  • Abbott
  • Baxter International
  • CEL-SCI
  • Cipla
  • Crucell
  • Denka Seiken
  • Green Cross
  • Hualan Biological Engineering
  • iBio
  • Imunoloski Zavod
  • Inovio Biomedical
  • Lupin
  • Medicago USA
  • Merck
  • Mitsubishi Tanabe Pharma
  • Omnivest
  • Panacea
  • Pfizer
  • Protein Sciences
  • Serum Institute of India
  • Sinovac Biotech
  • Solvay
  • Zhejiang Tianyuan Bio-pharmaceuticals
  • Zydus Cadila
Market driver
  • Global action plan for influenza vaccines
  • For a full, detailed list, view our report
Market challenge
  • Vaccine storage and handling issues
  • For a full, detailed list, view our report
Market trend
  • Improved understanding of immunology
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global H1N1 Vaccines Market 2016-2020

Technavio recognizes the following companies as the key players in the global H1N1 vaccines market: Sanofi, GSK, Astra Zeneca, and CSL.

Other Prominent Vendors in the market are: Abbott, Baxter International, CEL-SCI, Cipla, Crucell, Denka Seiken, Green Cross, Hualan Biological Engineering, iBio, Imunoloski Zavod, Inovio Biomedical, Lupin, Medicago USA, Merck, Mitsubishi Tanabe Pharma, Omnivest, Panacea, Pfizer, Protein Sciences, Serum Institute of India, Sinovac Biotech, Solvay, Zhejiang Tianyuan Bio-pharmaceuticals, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “One trend that is boosting market growth is an improved understanding of immunology. Technological advances and improved understanding of immunology and immunotherapy have enabled the discovery of biomarkers. This has aided in developing therapy through natural body defense mechanisms. Therapeutic vaccines that are capable of inducing the immune system to attack the targeted diseased tissue with greater bioavailability and specificity and minimal side effects associated with therapeutic drugs are being developed. Therapeutic vaccines are considered as viable alternatives to the existing therapeutic approaches.”

According to the report, a key growth driver is the global action plan for influenza vaccines. In a 2006 consultation, WHO, in collaboration with vaccine manufacturers, academic experts, public health organizations and funding agencies from developed and developing countries, developed the global action plan for influenza vaccines. The plan was intended to combat the global shortage of seasonal epidemic influenza vaccines and pandemic influenza vaccines. It is a comprehensive strategy focused on the increase in seasonal vaccine use and vaccine production capacity, and R&D for influenza vaccines. WHO is working to promote the use of influenza vaccines by encouraging its member states to develop a policy for influenza vaccination. Further, the organization is strengthening global surveillance systems to accurately analyze the circulating strains of influenza virus and determine the global burden of disease.

Further, the report states that one challenge that is hampering market growth is vaccine storage and handling issues. Inadequately stored vaccines lose their effectiveness to protect against diseases and can cause increased local reactions.



Companies Mentioned

Sanofi, GSK, Astra Zeneca, CSL, Abbott, Baxter International, CEL-SCI, Cipla, Crucell, Denka Seiken, Green Cross, Hualan Biological Engineering, iBio, Imunoloski Zavod, Inovio Biomedical, Lupin, Medicago USA, Merck, Mitsubishi Tanabe Pharma, Omnivest, Panacea, Pfizer, Protein Sciences, Serum Institute of India, Sinovac Biotech, Solvay, Zhejiang Tianyuan Bio-pharmaceuticals, Zydus Cadila.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria for H1N1 vaccines
  • Disease overview
    • Understanding the disease
    • Causes of H1N1 diseases
    • Signs and symptoms
      • Table Pediatric influenza vaccine price list 2015
      • Table Adult influenza vaccine price list 2015
  • Regulatory scenario of vaccines
    • Table Requirements for a BLA submission
    • Table Different types of development necessary to reach the vaccine licensing stage
    • Table Typical vaccine development process (over a period of up to 15 years and at a cost of up to $1
    • Table Regulatory testing of licensed vaccines
  • WHO recommendations for H1N1 vaccines
    • Key H1N1 virus vaccines for 2014-2015 season in US
    • H1N1 virus vaccines approved in EU
  • Reimbursement for influenza vaccines in US
    • The US healthcare reform
      • Table Comparison of US healthcare system before and after reforms
    • Reimbursement for influenza vaccines
      • Table Coding options for diagnosis of influenza vaccines
      • Table Medicare (Part B) current procedural terminology (CPT) codes for influenza vaccines
  • Reimbursement for influenza vaccines in other major countries
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Japan
  • Market landscape
    • Global human vaccines market
      • Table Top 10 pharmaceutical companies based on global vaccines market revenues 2015 ($ billions)
      • Table Global human vaccines market 2015-2020 ($ billions)
      • Table Market share of H1N1 vaccines markets in global human vaccines market 2015
    • Global H1N1 vaccines market
      • Table Global H1N1 vaccines market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by ROA
    • Table Global H1N1 vaccines market segmentation by ROA
    • Intramuscular vaccines
    • Intranasal vaccines
    • Intradermal vaccines
      • Table Global H1N1 vaccines market segmentation by ROA 2015
  • Geographical segmentation
    • Global H1N1 vaccines market by geographical segmentation 2015-2020
      • Table Global H1N1 vaccines market by geography 2015
      • Table Global H1N1 vaccines market by geography 2020
      • Table Global H1N1 vaccines market revenue by geography 2015-2020 ($ billions)
      • Table Percentage share of H1N1 vaccines market by geography 2015-2020
      • Table Global H1N1 vaccines market: YoY revenue and growth based on geography 2015- 2020 ($
    • H1N1 vaccines market in Americas
      • Table H1N1 vaccines market in Americas 2015-2020 ($ billions)
    • H1N1 vaccines market in EMEA
      • Table H1N1 vaccines market in EMEA 2015-2020 ($ millions)
    • H1N1 vaccines market in APAC
      • Table H1N1 vaccines market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Global action plan for influenza vaccines
    • Increase in R&D
      • Table A few pipeline molecules for H1N1 vaccines
    • Inclusion in NIP
    • Rise in awareness
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Antigenic drift and shift of H1N1v virus
    • Vaccine storage and handling issues
      • Table A typical cold chain process
    • Stringent regulatory guidelines
    • Emergence of local players
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Universal influenza vaccine
    • Emergence of quadrivalent vaccines
    • Increase in strategic alliances and M&A
      • Table Overview of major H1N1 vaccine-related acquisitions 2005-2012)
    • Improved understanding of immunology
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Market share analysis of global H1N1 vaccines market 2015
    • Sanofi
      • Table Sanofi: YoY revenue growth of influenza vaccines 2013-2015 ($ billions)
      • Table Sanofi: Geographic segmentation of influenza vaccines 2015
      • Table Sanofi: Key takeaways
    • GSK
      • Table GSK: YoY revenue and growth rate of Fluarix and FluLaval 2013-2015 ($ millions)
      • Table GSK: Geographical segmentation of Fluarix and FluLaval 2015
      • Table GSK: Key takeaways
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Fluenz 2013-2015 ($ millions)
      • Table AstraZeneca: Geographical segmentation of Fluenz 2015 ($ millions)
      • Table AstraZeneca: Key takeaways
    • CSL
      • Table CSL: YoY revenue and growth rate of influenza vaccines 2013-2015 ($ millions)
      • Table CSL: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report